There is considerable promise in enhancing the targeting and efficiency of metal-chelators through ligand design. Ligands can significantly alter the biological properties by modifying reactivity or substitution related inertness. Among heterocyclic moieties, pyrazole showed promising anticancer effects and in the 1960s, it was evaluated in Phase I studies as an antitumour agent in man, but, with doses of 0.15 mmol/kg/day it proved too toxic for human use because of development of signs of hepatotoxicity [17]. In search for better antitumour treatment, a large series of pyrazole derivatives were synthesized and tested over the years and the use of this powerful pharmacophore has become very popular and modern [18] and [19]. In the last decade several pyrazole derivatives proved to have potent anticancer action by the inhibition of the cyclin-dependent kinases (CDKs) that are members of the large family of protein kinases. CDKs are responsible for the eukaryotic cell cycle regulation and are intensively studied for their cancer implication [20] and [21].